CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...